Avant Technologies Completes Rebranding with Name Change to Avaí Bio and Launch of New Website
Rhea-AI Summary
Avaí Bio (OTCQB: AVAI) completed its corporate name change from Avant Technologies effective February 11, 2026, and launched a new website at https://www.avaibio.com. The rebrand aligns the company with its focus on cell-based therapies for type 1 and insulin-dependent type 2 diabetes, age-related diseases, and healthy longevity.
Key pipeline elements include genetically modified insulin-producing cell lines with proprietary encapsulation for immune protection, an α-Klotho overexpression program targeting aging, and strategic joint ventures Insulinova and Klothonova to advance clinical translation. The company confirmed its common stock will continue trading under AVAI with no CUSIP change.
Positive
- Corporate name change to Avaí Bio effective February 11, 2026
- Pipeline includes genetically modified insulin-producing cell lines plus proprietary encapsulation
- Formation of strategic joint ventures Insulinova and Klothonova to drive clinical translation
Negative
- No clinical trial timelines, enrollment targets, or regulatory milestones disclosed in the announcement
News Market Reaction
On the day this news was published, AVAI gained 0.82%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
The Company's common stock will continue trading under the ticker symbol AVAI on OTC Markets, with no change to the CUSIP number. Shareholders, partners, and investors can now access the updated corporate identity and comprehensive pipeline details at the new website: https://www.avaibio.com.
"This name change marks a defining moment in our evolution from a technology-focused entity to a dedicated biotechnology innovator at the forefront of cellular medicine," said Chris Winter, CEO of Avaí Bio. "Avaí Bio better captures our mission to deliver life-changing therapies that address unmet needs in diabetes management, age-related diseases, and anti-aging. By leveraging genetically engineered cell lines, state-of-the-art encapsulation to shield cells from immune rejection, and strategic joint ventures, we are positioned to accelerate progress toward functional cures and extended healthy lifespans."
Key elements of Avaí Bio's pipeline include:
Diabetes Development Program: Genetically modified cell lines engineered to produce, store, and secrete insulin, combined with proprietary encapsulation for immune protection—aiming to provide a sustainable, immunosuppression-free solution for type 1 and insulin-dependent type 2 diabetes.
α-Klotho Development Program: Advancement of a "longevity protein" overexpression cell line to combat age-related decline, targeting broader anti-aging and chronic disease applications.
Strategic collaborations, including the formation of Insulinova (diabetes program) and Klothonova (α-Klotho program) to drive clinical translation through joint research, licensing, and encapsulation expertise.
By rebranding to Avaí Bio, the Company aligns its corporate identity with its core operations in sourcing, developing, and protecting advanced cellular therapies—positioning it to attract top-tier partnerships, accelerate R&D, and bring groundbreaking treatments closer to patients.
About Avaí Bio, Inc.
Avaí Bio, Inc. is an emerging biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements developing innovative cell-based therapies.
More information about Avaí Bio can be found at https://www.avaibio.com
You can also follow us on social media at:
https://x.com/AvaiBio
https://www.facebook.com/AvaiBio
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avaí Bio, Inc.
info@avaibio.com
Logo: https://mma.prnewswire.com/media/2902043/Avai_Bio_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/avant-technologies-completes-rebranding-with-name-change-to-avai-bio-and-launch-of-new-website-302685166.html
SOURCE AVAI Bio Inc.
FAQ
What did Avaí Bio (AVAI) announce on February 11, 2026?
Will Avaí Bio (AVAI) ticker or CUSIP change after the rebrand?
What are Avaí Bio's (AVAI) diabetes program specifics described in the announcement?
What is Avaí Bio's (AVAI) α-Klotho program and its intended use?
How will the Insulinova and Klothonova collaborations affect Avaí Bio's (AVAI) development plans?
